Intriguingly, when we inoculated murine breast cancer cells (4T1) into a syngeneic mouse model, we repeatedly confirmed the reduction in tumor growth induced by DCLK1-IN-1 treatment without any signs of side effects, along with significant reductions in PGE2 levels and gene expression associated with the microenvironmental effects of PGE2 (Figure S9D-I). This evidence concerns the gene DCLK1 and breast cancer.